|
|
||||||||
Department of Microbiology, University of Tennessee, Knoxville, TN 37996
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
early in the experimental disease may alleviate lesion severity (5, 6). Whether or not dedicated cell types that produce anti-inflammatory cytokines enter the cornea and regulate responses has not been explored. Thus, conceivably this viral-induced immunopathology, like several autoimmune lesions, might be subject to control by regulatory T cells (Treg)3 such as the CD4+CD25+ Treg population described initially by Sakaguchi et al. (7, 8, 9). To date, the role of CD4+CD25+ Treg in the pathogenesis of viral immunopathological disease has not been reported. Our results demonstrate a major role for CD4+CD25+ Treg cells in the pathogenesis of murine herpetic stromal keratitis (HSK). We demonstrate that Treg depletion before infection results in lesions of greater severity and the induction of disease with lower infecting doses of virus. However, the role of CD25+ Treg in HSK pathogenesis was complex. One effect was to minimize the extent of immunopathogenic CD4+ T cell induction, whereas another was to limit the migration of pathogenic T cells to the tissue inflammatory site. The CD25+ Treg were present in the ocular inflammatory sites, could be recovered from the site, and were shown to express IL-10-dependent inhibitory effects on activated CD4+ T cells in vitro. Our results indicate that CD25+ Treg play a beneficial role to minimize viral immunological lesions and imply that procedures that enhance their function may prove therapeutically beneficial.
| Materials and Methods |
|---|
|
|
|---|
Female 5- to 6-wk-old C57BL/6, Thy1.2+ BALB/c, and BALB/c SCID (H-2d) mice were purchased from Harlan Sprague Dawley (Indianapolis, IN) and Thy1.1+ BALB/c mice were a kind gift from Dr. D. Woodland (Trudeau Institute, Saranac Lake, NY) and housed in the animal facilities at the University of Tennessee. SCID mice were kept in our special pathogen-free facility where all food, water, bedding, and instruments were autoclaved and all manipulations were done in a laminar flow hood. All experimental procedures were in complete agreement with the Association for Research in Vision and Ophthalmology resolution on the use of animals in research. HSV-1 RE was propagated and titrated on Vero cells (ATCC CCL81) using standard protocols. The virus was stored in aliquots at -80°C until use.
Abs and reagents
PC61 (anti-CD25) hybridoma was purchased from American Type Culture Collection (Manassas, VA) and Ab was grown in tissue culture roller bottles. For all injections, an ammonium sulfate cut of PC61 mAb (1.0 mg/mice) was used. Abs purchased from BD PharMingen (San Diego, CA) were FITC, PE, and biotin anti-CD4, FITC anti-CD25 (7D4), PE-anti-CD25 (PC61), CD62 ligand, CD44, CD69, CD49d, CTLA-4, streptavidin-PerCP-Cy5.5, and ELISA Abs such as anti-IFN-
, anti-IL-2, anti-IL-10, and their biotinylated counterparts.
In vivo depletion, corneal HSV-1 infections, and clinical observations
BALB/c mice were given 1.0 mg PC61 mAb i.p. 3 days before corneal infection. Initial kinetics of depletion was studied in uninfected mice. Corneal infections of PC61-treated or nontreated BALB/c mice were conducted under deep anesthesia. Mice were scarified on their corneas with a 27-gauge needle, and a 3-µl drop containing the required viral dose was applied to the eye. The eyes were examined on different days postinfection (p.i.) with a slit-lamp biomicroscope (Kowa, Nagoya, Japan), and the clinical severity of keratitis of individually scored mice was recorded. The scoring system was as follows: +1, mild corneal haze; +2, moderate corneal opacity or scarring; +3, severe corneal opacity, but iris visible; +4, opaque cornea, iris invisible; and +5, necrotizing SK.
Immunofluorescence and immunohistochemical staining
Eyes were frozen in OCT compound (Miles, Elkart, IN) at different days p.i. Six-micrometer-thick sections were cut, air dried, and fixed in cold acetone for 5 min. The sections were then blocked with 3% BSA and stained for the presence of CD4+ T cells and neutrophils with their respective mAbs. For immunohistochemistry, the biotinylated primary Abs were used followed by HRP-conjugated streptavidin, (1/1000; Jackson ImmunoResearch Laboratories, West Grove, PA) and 3,3'-diaminobenzidine (Vector Laboratories, Burlingame, CA). In the case of immunofluorescence, the frozen sections were fixed in 4% paraformaldehyde and the primary Ab was labeled with FITC. Finally, sections were washed with PBS and mounted with Vectashield mounting medium with propidium iodide (Vector Laboratories).
Flow cytometric analysis
Cell preparation. Single-cell suspensions were prepared from the cornea, draining lymph nodes (DLN), and spleen of mice at different time points p.i. Corneas were digested with Liberase (Roche Diagnostics). Briefly, a small incision was made at the junction of the limbus and the corneal cap was carefully removed. The pooled corneas were incubated with 60 U/ml Liberase for 60 min at 37°C in a humidified atmosphere of 5% CO2. After incubation, the corneas were disrupted by grinding with a syringe plunger on a stainless steel mesh and a single-cell suspension was made in complete RPMI 1640 medium. Cells were counted with trypan blue exclusion with high viability.
Staining for flow cytometry. The single-cell suspension obtained from DLN, and corneal samples were stained for different cell surface molecules for FACS. Briefly, a total of 1 x 106 cells were first blocked with an unconjugated anti-CD32/CD16 mAb for 30 min. in FACS buffer followed by addition of fluorochrome-labeled respective Abs for an additional 45 min. For intracellular staining, surface-labeled cells were permeabilized with permeabilization buffer (BD Biosciences, Mountain View, CA) and fluorochrome-labeled mAb was added. Finally, the cells were washed three times and samples were acquired on a FACScan (BD Biosciences). The data were analyzed using the CellQuest 3.1 software (BD Biosciences).
Cytokine ELISA
The culture supernatants from the bulk test cultures without addition of any exogenous cytokines were screened for the presence of IL-10 and IL-2 and IFN-
. Briefly, ELISA plates were coated with capture Abs (2.0 µg/ml) in 0.1 M Na2HPO4 (pH 9.0) for the respective cytokines and incubated at 4°C overnight. The plates were washed with PBS-Tween 20 and blocked with 3% BSA for 2 h at room temperature. After washing, serially diluted samples and standards were added to the plate and incubated at 4°C overnight. The plates were washed followed by the addition of cytokine-specific detection Abs for 2 h. Finally, peroxidase-conjugated streptavidin (Jackson ImmunoResearch) was added at 1/1000 dilutions. The color was developed by adding the substrate (ABTS) solution (Sigma-Aldrich, St. Louis, MO) and the concentration was calculated with an automated ELISA reader (SpectraMAX 340; Molecular Devices, Sunnyvale, CA).
Quantification of IL-2- and IFN-
-secreting cells by ELISPOT
The ELISPOT assay was used for quantification of cytokine-producing cells as reported earlier (11). Briefly, ELISPOT plates (Millipore, Molseheim, France) were coated overnight at 4°C with anti-mouse IL-2 and IFN-
Ab in 0.1 M Na2HPO4 (pH 9.0). CD4+ T cells (responder cells) obtained from virus-infected mice were mixed with syngeneic splenocytes (stimulator cells) pulsed earlier with UV-inactivated HSV (multiplicity of infection, 5.0) for 3 h along with 10 U/well human IL-2. Coincubation of the responder and stimulator cells was continued for 48 h at 37°C. The ELISPOT plates were washed three times with PBS and three times with PBS-Tween 20 (PBST), followed by addition of biotinylated IL-2 and IFN-
Ab (1 µg/ml) for 1 h at 37°C. The spots were developed using nitroblue tetrazolium (Sigma-Aldrich) and 5-bromo-4-chloro-3-indolylphosphate (Sigma-Aldrich) as a substrate following incubation with alkaline phosphatase-conjugated streptavidin (Jackson ImmunoResearch) for 1 h and counted 24 h later under a stereomicroscope.
CD4+CD25+ Treg and CD4+CD25neg T cell purification and adoptive transfer into BALB/c SCID mice
CD4+CD25+ Treg were purified as reported by others (36). Briefly, CD4 columns (R&D Systems, Minneapolis, MN) were used for the isolation of CD4+ T cells. CD4+CD25+ Treg were then purified by incubating the enriched CD4+ T cells obtained from the spleen and lymph node with biotin-conjugated anti-CD25 (15 µg/108 cells) mAb in PBS-2% FCS for 15 min at 4°C. Positive magnetic separation was then performed with LS+ columns (Miltenyi Biotec, Auburn, CA) according to the suggested protocol. The purity of cells ranged from 8595%. The purified naive CD4+CD25- T cells were adoptively transferred into SCID mice either alone or with CD25+ Treg 24 h before virus infection. Immune responses were analyzed 12 days p.i. Primed CD4+CD25- T cells were also purified by the same procedure 4 wk after HSV (i.p) infection. In some experiments, corneal CD4+CD25+ T cells were purified by FACS sorting. Briefly, 32 corneal samples were collagenase digested and MACS-purified CD4+ T cells were sorted into CD25+ and CD25- fractions. The purity of sorted fractions was >95%.
Proliferation assay
The purified CD4+CD25+ Treg or CD4+CD25neg T cells (5 x 103/well) were cultured with soluble anti-CD3 mAb (1.0 µg/ml) along with irradiated spot-forming cells (SPC) in the presence or absence of IL-2 (20 U/ml) for 72 h in 96-well round-bottom plates. To assess suppression by CD25+ Treg, a graded number of Treg were added into the anti-CD3 mAb-stimulated culture of CD4+CD25neg T cells (104 cells/well) in the presence of irradiated SPC. In one particular experiment, anti-IL-10R mAb (10 µg/ml) was added to a CD25+ Treg (104/well) and CD25neg T cell (104/well) coculture in the presence of anti-CD3 and irradiated SPC. Finally, [3H]thymidine (ICN Radiochemicals, Irvine, CA) was added 1 µCi/well for the last 18 h. The plates were harvested and were read using a beta scintillation counter (Trace 96; Inotech, Wohlen, Switzerland). The results were expressed as mean cpm ± SD.
Real-time quantitative PCR
The total cellular RNA was isolated form corneas by using an RNeasy protect mini kit (Qiagen, Valencia, CA) according to the manufacturers instruction. All samples were treated with RNase-free DNase (Qiagen). The extracted RNA was reverse transcribed using oligo(dt) primers and reverse transcriptase enzyme (Promega, Madison, WI) according to standard protocol (4). The cDNA obtained was used as a template for real-time quantitative PCR and real-time PCR was performed using a Quantitect SYBR green PCR kit (Qiagen). Initially, mRNA levels were normalized to the GAPDH mRNA level. PCR primer pairs used for GAPDH were 5'-GCC TGC TTC ACC ACC TTC TTG ATG-3' and 5'-CAT CCT GCA CCA CCA ACT GCT TAG-3'. Foxp3 expression was measured by using primers 5'-GGC CCT TCT CCA GGA CAG A-3' and 5'-GCT GAT CAT GGC TGG GTT GT-3'. Briefly, for real-time PCR, a standard curve was generated using the PCR product of Foxp3 cloned into a pCR-XL-TOPO vector (Invitrogen, San Diego, CA). After spectrophotometric determination of the plasmid DNA concentration, the copy number was calculated using the following formula: (X g/µl DNA/(plasmid length in bp x 660]) x 6.022 x 1023 = Y molecules/µl. Test samples were run in triplicate with a dilution series and the mean value of a particular dilution was used. Data are expressed as copy number per sample.
Statistical analysis
All analysis for statistically significant differences were performed with a Students paired t test. Values of p < 0.01 and p < 0.05 were considered to be statistically significant. Results are expressed as mean ± SD.
| Results |
|---|
|
|
|---|
BALB/c mice were treated with the PC61 mAb using conditions in which >90% of CD4+CD25+ cells were depleted by day 3 and
4050% depleted at 18 days after depletion (data not depicted). Three days posttreatment, mice were infected on the ocular surface with different doses of HSV-1 and the severity of their stromal keratitis (SK) lesions were compared with age-matched control-infected mice treated with isotype control rat Ig. The results of a representative experiment are shown in Fig. 1a. As is evident, CD25-depleted animals developed more severe lesions, an effect most apparent in animals infected with a lower dose (104 PFU/eye) of virus. In this instance, 60% of eyes from depleted animals had lesion severity scores of 3.0 or greater on day 15 p.i. compared with none in the nondepleted animals (p < 0.01). A similar pattern of results was noted when comparing lesion severity in the HSV-resistant C57BL/6 mouse strain (Fig. 1b). In these experiments, CD25+ Treg depletion resulted in approximately a 10-fold greater susceptibility to ocular HSV infection with an infecting dose of virus (105 PFU/eye) producing lesions in depleted, but not in undepleted animals.
|
SK is well known to be orchestrated by CD4+ T cells (1). As shown in Table I, the percentage of CD4+ T cells recovered by collagenase digestion of corneas was greater in Treg-depleted animals at all time points tested after ocular HSV infection. Sample animals evaluated by immunocytochemistry at the time of peak lesions (day 15) are shown in Fig. 2a. Increased T cell infiltration was notably more evident in sections from Treg-depleted animals.
|
|
2-fold increase in CD49d+CD4+ T cells. Additional experiments were conducted to compare the effector functions of infiltrated ocular CD4+ T cells in the nondepleted and Treg-depleted mice. On day 15 p.i., cells isolated from collagenase-digested corneal tissue were stimulated with anti-CD3 mAb in the presence of IL-2 for 16 h. As shown in Fig. 2c, the percentage of ocular CD4+ T cells express more IFN-
in the CD25-depleted group compared with the nondepleted group. Taken together, we interpret these observations to mean that after viral infection, Treg may control the expression of molecules such as CD49d that are involved in migration of inflammatory cells to the ocular lesion site (10). Furthermore, once effector cells reach the cornea they function more effectively if not hampered by the presence of Treg. Treg depletion results in enhanced immune responsiveness to HSV
Another explanation for heightened lesion severity of Treg-depleted animals could be that these animals developed enhanced HSV-specific immune responses. As demonstrated in Fig. 3, specific responses of both splenic and DLN CD4+ T cell were
2-fold higher in Treg-depleted animals compared with controls as measured by ELISA and ELISPOT analysis for both IL-2 and IFN-
. Thus, as noted previously with the specific CD8+ T cell response to HSV (11), Treg depletion also results in elevated CD4+ T cell immunity to HSV.
|
Mice lacking T cells fail to express SK upon ocular infection with HSV, but readily do so if given adoptive transfers of CD4+ T cells (12). To assess the influence of Treg on this form of immunopathology, CD25+ T cells were isolated from naive BALB/c mice and transferred into SCID recipients along with a population of CD4+CD25neg T cells from either naive or animals primed 5 wk previously by HSV infection. Mice were then infected ocularly with HSV. The results expressed in Fig. 4a indicate that the lesions induced by both naive and primed CD4+CD25neg T cells were reduced in severity if animals additionally received Treg. The effect was greater against the naive cells than against the primed population, but in both instances the differences were statistically significant (p < 0.01). In these experiments, the transfer of Treg alone failed to cause SK and animals in this group died earlier from HSV encephalitis than those in the other groups. Curiously, the adoptive transfer recipients of both Treg and CD25neg T cells also had less neutrophil infiltration in their inflammatory lesions (Fig. 4b). This might mean that the Treg additionally function in the eye to limit innate aspects of immunity.
|
The mechanism by which the adoptive transfer of CD25+ Treg suppressed lesion induction by CD25neg primed and naive CD4+ T cells was further investigated and seen to have at least two explanations. First, as shown in Fig. 5a, cotransfer of Treg with CD25neg T cells resulted in significantly diminished Th1-type immune responses in viral Ag-stimulated splenocytes. This effect was more evident against the response of naive CD25neg cells (
4-fold reduction) than against primed cells (
2-fold reduction). In neither group could Ag-induced IL-10 production be demonstrated in splenocytes (data not depicted). Such results indicate that the Treg served to inhibit the induction of HSV immunopathogenic CD4+ T cells involved in lesion expression.
|
In these experiments, lesion severity was greater in control animals given only CD25neg T cells compared with those that additionally received Treg (data not depicted). FACS analysis of splenocytes from animals in the two groups revealed that the adoptively transferred Thy1.2 cells showed phenotypic differences. Thus, whereas 49.0% of Thy1.2 cells in recipients of only CD25neg T cells were positive for CD49d, those that additionally received Treg had significantly fewer CD49d-positive Thy1.2 cells (19.0%; Fig. 5b). In addition, random corneal samples were taken from both groups and either stained by immunohistochemistry (Fig. 5c) or collagenase digested to quantitate the influx of CD4+ T cells (Fig. 5d). The presence of Treg strongly diminished the number of CD4+ T cells in virus-infected corneas. Similar results were observed when naive CD4+CD25neg T cells were adoptively transferred with Treg into SCID mice (data not depicted). Since
70% of ocular CD4+ T cells express CD49d, at least in the early phase of SK lesions (Fig. 2b), we interpret these experiments to indicate that Treg may down-regulate CD49d in lymphoid organs and that in consequence fewer cells were able to migrate to the ocular damage site. Interestingly, we also observed that adoptively transferred CD4+CD25+ regulatory T cells expressed very high levels of CD49d (data not shown), a molecule involved in the migration of cells to the eye (10).
CD4+CD25+ Treg are present in SK lesions
In autoinflammatory lesions that are subject to control by CD25+ Treg, it remains unclear whether Treg are present in lesions and exert their effects at such extralymphoid tissue sites or whether they act only in lymphoid tissues (13, 14). Two approaches indicated that in the SK model, Treg were present in tissue lesions. The first approach took advantage of the observation that CD25+ Treg express higher levels of intracellular CTLA-4 and lower cell surface expression of CD45RB (15). At 15 days p.i., corneal inflammatory cells were recovered by collagenase digestion and analyzed by FACS for their CD4, CD25, CD45RB, and intracellular CTLA-4 phenotype. In populations from undepleted animals, an average of 35% of CD4+ cells were CD25+ and all expressed higher levels of CTLA-4. Additionally, they possessed lower levels of CD45RB (Fig. 6a). However, in ocular cells of CD25-depleted animals, an average of 12% of CD4+ cells were CD25+ and they expressed significantly lower levels of CTLA-4 and higher levels of CD45RB than cells from intact animals (Fig. 6a). These results indicate that Treg may migrate to the site of inflammation in virus-infected undepleted animals.
|
Role of lesion CD4+CD25+ Treg in controlling SK
To seek evidence that the lesion Treg in undepleted animals expressed immunomodulatory activity, cells were collected and fractionated into CD4+CD25neg and CD4+CD25+ T cells. The cell fractions were then tested for their ability to proliferate in response to a polyclonal stimulant, soluble anti-CD3 mAb. The CD25neg population underwent extensive proliferation but the CD25+ cells proliferated only when exogenous IL-2 was added (Fig. 7a). Furthermore, the addition of graded numbers of ocular CD25+ cells to a fixed number of ocular CD25neg responders showed a dose-dependent inhibition of anti-CD3-driven proliferation of the CD25neg cells (Fig. 7b).
|
| Discussion |
|---|
|
|
|---|
The surge of recent interest in regulatory cells has primarily focused on disease models that involve autoreactivity (18, 19). However, increasing reports document that Treg also influence immunity to several pathogens (11, 20, 21). Thus, we and others have shown that the absence of a Treg response may result in heightened immunity which includes a more durable memory response (11, 22). However, a downside of heightened immune reactivity might be immunopathogenesis. Indeed, the initial description of CD25+ Treg cell function emerged from studies showing that their absence resulted in organ-specific autoimmune diseases in an adoptive transfer system (7). The SK model represents a situation where normally immunoprotective CD4+ T cells exert an immunopathological function in the special environment of the eyes cornea (23). Thus, for reasons still unclear, corneal infection with HSV sets off an inflammatory reaction that usually fails to fully resolve, even long after viral replication has ceased and viral Ags are no longer detectable (24). Such observations have led to the suggestion that SK ultimately becomes an autoinflammatory lesion (25), but this attractive hypothesis remains to be substantiated.
Our observation that the severity of SK lesions was influenced by Treg was supported by the observation of more severe lesions in Treg-depleted animals, as well as by noting a modulatory effect of Treg on lesions induced by pathogenic CD4+ T cells in an adoptive transfer system. Our results suggest that Treg may play a pivotal role in microbial pathogenesis, especially in situations that involve chronic inflammation and persistent infection. Other examples have also been recently reported, especially with parasitic infections (26, 27). Thus, with Leishmania infection in the susceptible BALB/c mouse strain, Treg appeared to limit the extent of T cell-mediated inflammatory disease (28). This is similar to the circumstances we described for SK as well as for Pneumocystis carnii-induced lung pathology in mice (21). However, in resistant mice the Treg plays a crucial role in maintaining concomitant immunity to Leishmania (20). Accordingly, Treg limit the protective effect of CD4+ Th1 cells, resulting in a balance that permits parasite persistence, immunity to reinfection, and an absence of lesions. Removal of Treg results in parasite clearance but susceptibility to infection. Clearly, manipulating Treg function in chronic microbial infections could represent a valuable approach to disease management.
Although our results substantiate that Treg modulate the severity of SK lesions, we can only speculate how this process is accomplished. We anticipate that the effects are multiple. They include inhibition of virus-specific CD4+ T cell induction, the cells that help orchestrate SK lesions (3). Accordingly, the presence of Treg limited the extent of CD4+ T cell immunity, as was shown previously to occur with CD8+ T cell responses (29). In immunocompetent mice, these inhibitory effects were modest. Greater effects were evident in an adoptive transfer model in which Treg were transferred along with naive or primed CD4+CD25neg responders and HSV-specific immunity was compared with recipients that received responder cells only. In such experiments, the HSV-specific CD4+ T cell response was inhibited by up to 4-fold in animals that received Treg. Thus, one explanation for the Treg effect on SK lesion expression was immunosuppression, an effect likely mediated at the lymphoid sites of immune induction.
A second effect accounting for reduced lesion severity could be that Treg, perhaps as a consequence of activation by HSV as was shown to occur previously (11), could serve to modulate the expression of one or more homing molecules involved in T cell migration to the ocular inflammatory site. Although the signature of homing molecules involved in ocular migration remains unknown, there is evidence that the integrin VLA-4 is involved in the process (10). In addition, in SK 7080% of corneal T cells in disease express VLA-4 early in lesion development. Thus, it was intriguing to observe that the VLA-4 integrin was expressed on a significantly lower percentage of lymphoid CD4+ T cells when these were activated in the presence of Treg. Our observations could mean that Treg also act to control lesion development by limiting the migration of pathogenic T cells to the extralymphoid inflammatory site. Such concepts are now under further investigation.
A final effect of Treg on SK may be that such cells also function at tissue sites to limit inflammatory events. Whether or not Treg act at nonlymphoid or lymphoid sites (or both) remains an unresolved issue. In some systems where Treg effects have been noted, the regulatory cells cannot be demonstrated in lesions (14). In others they are present, but it was not clear whether this was the exclusive site for their activity. For example, in the inflammatory bowel disease model, Treg could be demonstrated both in colon lesions as well as in the mesenteric lymph nodes, but whether they act at both sites was not evaluated (13). In the SK model, two lines of evidence indicated that Treg were present in tissues. First, a high percentage of CD4+CD25+ T cells isolated from lesions of undepleted mice also expressed high intracellular CTLA-4 and low cell surface expression of CD45RB, accepted markers for Treg (15). Additionally, taking advantage of the recent observation that the transcription factor Foxp3 is a marker product for Treg (16), we showed by real-time PCR abundant Foxp3 message only in the samples from nondepleted mouse lesions. Together, these approaches indirectly establish the presence of Treg in lesions, but do not indicate that they act to control immunopathology at the site.
Two lines of evidence indicated that such lesional Treg were functioning in the SK system. First, the homing/activation marker VLA-4 was expressed on a significantly lower percentage of lesional CD4+ T cells late after infection (15 days p.i.) in control compared with undepleted animals. This could mean that the Treg were responsible for down-regulation. Second, CD25+ T cells isolated from lesions at this late stage were shown to inhibit in vitro proliferation of polyclonal stimulated CD4+CD25neg T cells isolated from the same lesions. This modulatory effect was partially inhibited by anti-IL-10R mAb, indicating that the Treg acted via IL-10 secretion as noted in some other systems (30, 31).
Further studies are underway to directly demonstrate Treg in SK lesions and to determine whether and how they control the immunopathology. We anticipate that the efficacy of such a function might vary as lesions progress. Conceivably, regulation may not occur in the early lesions when virus is still present because HSV infection is a potent stimulus for IL-6 production (32, 33), and this cytokine was elegantly shown to render pathogenic T cells refractory to the effects of Treg (34). Furthermore, the corneal IL-6 concentrations have also been reported to decline during the later phase of HSK (35), the time when Treg might help to resolve the inflammatory events. The kinetics of Treg ingress and their control of SK lesions are under further investigations.
| Acknowledgments |
|---|
| Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Barry T. Rouse, Department of Microbiology, M409, Walters Life Sciences Building, University of Tennessee, Knoxville, TN 37996-0845. E-mail address: btr{at}utk.edu ![]()
3 Abbreviations used in this paper: Treg, T regulatory cell; SK, stromal keratitis; p.i., postinfection; HSK, herpetic stromal keratitis; DLN, draining lymph node; SPC, spot-forming cell; VLA, very late Ag. ![]()
Received for publication October 10, 2003. Accepted for publication January 30, 2004.
| References |
|---|
|
|
|---|
DNA. J. Clin. Invest. 102:438.[Medline]
-chains (CD25): breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155:1151.[Abstract]
This article has been cited by other articles:
![]() |
S. Sehrawat, S. Suvas, P. P. Sarangi, A. Suryawanshi, and B. T. Rouse In Vitro-Generated Antigen-Specific CD4+ CD25+ Foxp3+ Regulatory T Cells Control the Severity of Herpes Simplex Virus-Induced Ocular Immunoinflammatory Lesions J. Virol., July 15, 2008; 82(14): 6838 - 6851. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Sehrawat and B. T. Rouse Anti-Inflammatory Effects of FTY720 against Viral-Induced Immunopathology: Role of Drug-Induced Conversion of T Cells to Become Foxp3+ Regulators J. Immunol., June 1, 2008; 180(11): 7636 - 7647. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Lund, L. Hsing, T. T. Pham, and A. Y. Rudensky Coordination of Early Protective Immunity to Viral Infection by Regulatory T Cells Science, May 30, 2008; 320(5880): 1220 - 1224. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. N. Couper, D. G. Blount, and E. M. Riley IL-10: The Master Regulator of Immunity to Infection J. Immunol., May 1, 2008; 180(9): 5771 - 5777. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. P. Sarangi, S. Sehrawat, S. Suvas, and B. T. Rouse IL-10 and Natural Regulatory T Cells: Two Independent Anti-Inflammatory Mechanisms in Herpes Simplex Virus-Induced Ocular Immunopathology J. Immunol., May 1, 2008; 180(9): 6297 - 6306. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D. Smith, S. Botero, and O. A. Levander Copper Deficiency Increases the Virulence of Amyocarditic and Myocarditic Strains of Coxsackievirus B3 in Mice J. Nutr., May 1, 2008; 138(5): 849 - 855. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Divito and R. L. Hendricks Activated Inflammatory Infiltrate in HSV-1-Infected Corneas without Herpes Stromal Keratitis Invest. Ophthalmol. Vis. Sci., April 1, 2008; 49(4): 1488 - 1495. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Fernandez, F. K. Puttur, Y. M. Wang, W. Howden, S. I. Alexander, and C. A. Jones T Regulatory Cells Contribute to the Attenuated Primary CD8+ and CD4+ T Cell Responses to Herpes Simplex Virus Type 2 in Neonatal Mice J. Immunol., February 1, 2008; 180(3): 1556 - 1564. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. H. Nguyen, S. Shashidhar, D. S. Chang, L. Ho, N. Kambham, M. Bachmann, J. M. Brown, and R. S. Negrin The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation Blood, January 15, 2008; 111(2): 945 - 953. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Li, E. J. Gowans, C. Chougnet, M. Plebanski, and U. Dittmer Natural Regulatory T Cells and Persistent Viral Infection J. Virol., January 1, 2008; 82(1): 21 - 30. [Full Text] [PDF] |
||||
![]() |
P. K. Suvas, H. M. Dech, F. Sambira, J. Zeng, and T. M. Onami Systemic and Mucosal Infection Program Protective Memory CD8 T Cells in the Vaginal Mucosa J. Immunol., December 15, 2007; 179(12): 8122 - 8127. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. C. von Hertzen, P. T. Pekkarinen, T. Laatikainen, M. J. Makela, T. Haahtela, and for the Karelian Allergy Study Group Herpes simplex virus and atopy in Finnish and Russian Karelian children Eur. Respir. J., October 1, 2007; 30(4): 809 - 810. [Full Text] [PDF] |
||||
![]() |
J. D. Easterbrook, M. C. Zink, and S. L. Klein Regulatory T cells enhance persistence of the zoonotic pathogen Seoul virus in its reservoir host PNAS, September 25, 2007; 104(39): 15502 - 15507. [Abstract] [Full Text] [PDF] |